These therapeutics are of particular importance given the widespread association of YAP/TAZ activity with cancer progression and the preclinical evidence supporting the potential of inhibition of YAP/TAZ-TEAD driven expression in suppressing cancer growth. Here, WWTR1 is linked to cancer.